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Abstract
Background: Oncogenic RAS is a highly validated cancer target. Attempts at targeting RAS directly have so far not
succeeded in the clinic. Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will
help tailor treatments that use RAS-effector inhibitors either alone or in combination to target RAS-driven tumors.
Methodology/Principal Findings: In this study, we have investigated the sufficiency of targeting RAS-effectors, RAF, MEK
and PI3-Kinase either alone or in combination in RAS mutant lines, using an inducible shRNA in vivo mouse model system.
We find that in colon cancer cells harboring a KRAS
G13D mutant allele, knocking down KRAS alone or the RAFs in
combination or the RAF effectors, MEK1 and MEK2, together is effective in delaying tumor growth in vivo. In melanoma cells
harboring an NRAS
Q61L or NRAS
Q61K mutant allele, we find that targeting NRAS alone or both BRAF and CRAF in
combination or both BRAF and PIK3CA together showed efficacy.
Conclusion/Significance: Our data indicates that targeting oncogenic NRAS-driven melanomas require decrease in both
pERK and pAKT downstream of RAS-effectors for efficacy. This can be achieved by either targeting both BRAF and CRAF or
BRAF and PIK3CA simultaneously in NRAS mutant tumor cells.
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Introduction
Oncogenic mutations in the RAS family of small GTPases,
KRAS, HRAS and NRAS, occur in approximately a third of all
human cancers [1–3]. This makes RAS a prime target for drug
development. However, efforts at developing therapeutics that
target mutant RAS directly so far have not been very successful [2].
Understanding the signaling pathways engaged by oncogenic
RAS in promoting malignant transformation is fundamental to
identifying and targeting components downstream of RAS.
Several studies have helped identify major RAS effector molecules
which include the Raf kinases, class I phosphoinositide 3-kinases
(PI3K), Ral guanine nucleotide exchange factors (Ral-GEFs), Rac
exchange factor Tiam1, and phospholipase Ce [4,5].
The RAF kinases, members of the three-component MAP
Kinase cascade, once activated by GTP-bound RAS, phosphor-
ylate and activate dual-specificity kinases MEK1 and MEK2,
which in-turn activate MAP Kinases ERK1 and ERK2. Active
ERK1/2 then translocates to the nucleus to exert their biological
effects. PIK3CA, a PI3K family member stimulated through RAS
activation, phosphorylates its lipid substrate phosphatidylinositol
(4,5) bisphosphate (PIP2) to produce phosphatidylinositol (3,4,5)
triphosphate (PIP3). This phosphorylated lipid PIP3 is an
important cellular second messenger that promotes the activation
of AKT (AKT1, AKT2 and AKT3) leading to cell survival.
Besides mutations in RAS, activating somatic mutations in its
effectors PIK3CA and BRAF, occur in various human cancers
[6,7]. While PIK3CA mutations are more prevalent in colon and
breast cancer, BRAF mutation occurs at a high frequency in
melanoma [6,7]. Additionally, loss-of-function of the PTEN tumor
suppressor gene, which leads to activation of PI3-kinase, is
widespread in cancers [8]. Functional studies that dissect PIK3CA
and BRAF somatic mutations have established the oncogenic
nature of these RAS effector genes [9–11]. Further, these studies
show that each effector arm on its own when activated is sufficient
to promote tumor formation, especially, in tumor types where they
are commonly mutated. Interestingly, BRAF mutations are
mutually exclusive with NRAS mutations in melanoma and
KRAS mutations in colorectal cancer [7,12,13]. In contrast,
mutations in PIK3CA are not mutually exclusive with KRAS in
colorectal cancers [12,13]. The patterns of mutational co-
occurrence, suggests that each RAS-effector is differentially
employed in promoting tumor initiation in a tumor tissue specific
manner. A recent study using an engineered mouse model showed
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for initiation of lung tumors in a RAS-mutant mouse [14].
Similarly, in engineered human skin graft mouse models, the PI3K
effector arm was found to be equivalent to RAS in inducing
melanocytic neoplasia [15]. Another study, using engineered cell
lines that express various RAS-mutants that can preferentially
engage either RAF, PI3K or RalGEF showed that while all three
were important for tumor initiation, the PI3K pathway was
essential for tumor maintenance [16].
Pharmacological inhibitors that target RAS effectors, RAF and
PI3Ks, are in various stages of clinical trials [17,18]. Small
molecule inhibitors that target downstream components of these
effectors, MEK1/2 and AKT1/2/3 have been developed and are
undergoing tests in human trials as well [18–21]. Using
pharmacological inhibitors of PI3K and RAF effectors, various
studies have demonstrated the importance of either the PI3K or
RAF arms or the requirement for targeting both in RAS mutated
tumors [22–25]. In pancreatic epithelial cells, KRAS mediated
transformation requires both RAF and PI3K signaling [26]. In
NRAS mutated melanoma cells, CRAF was demonstrated to be
the major RAS effector for signaling through ERK [27,28]. These
along with the studies using engineered mouse models and cell
lines have yielded results that are often contradictory and
confounding, underscoring the importance of further in vivo studies
that address the relevance of these components in initiation,
maintenance and progression of cancers.
Using a recently described inducible shRNA system [29], we
have previously shown that signaling via oncogenic BRAF is
essential for tumor initiation and maintenance in melanoma
models [30]. In this study, we have used this inducible shRNA
system and in vivo xenograft mouse model to demonstrate the
effectiveness of targeting downstream RAS-effectors either alone
or in combination as strategies for treatment of RAS driven
cancers.
Results
Oncogenic RAS-mutant cancer cells require RAS for
proliferation, anchorage independent growth and tumor
formation
HCT116, a colon cancer line that harbors a KRAS
G13D
mutation and IPC298, a cutaneous melanoma cell line bearing an
NRAS
Q61L mutation, were chosen for this study since KRAS in
colorectal cancer and NRAS in melanoma is the most frequently
mutated RAS gene in these tumor types. The colon cancer cell line
HCT116, in addition to KRAS mutation, also harbors an
activating mutation in the RAS effector PIK3CA (Table S1). In
order to understand the relevance of oncogenic RAS and its
dependence on its major downstream effectors, RAF and PI3K,
we used a previously described doxycycline (dox)-inducible shRNA
system [29] to study the effects of RAS knockdown on cellular
proliferation and tumor growth. We generated pools of cells
expressing shRNAs that target RAS in a dox-inducible fashion.
Upon dox treatment RAS, KRAS in HCT116 and NRAS in
IPC298, was effectively silenced (Figure 1A). Consistent with the
loss of signaling from RAS, the levels of phospho ERK decreased
in both the RAS mutant lines, relative to the total ERK in these
lines. In addition to loss of phosphoERK levels, RAS knock-down
in both IPC298 and HCT116 cells led to a decrease in the
phospho AKT levels. Phospho AKT levels were reduced in KRAS
knock-down HCT116 cells despite the presence of PIK3CA
mutation in this line. In both lines the control luciferase shRNA-
expressing cells upon dox induction did not show any changes in
either the phospho or the total ERK levels. Similarly, the phospho
and total AKT levels were not modulated significantly in these
cells following dox addition. To determine the requirement of
RAS in these RAS-mutant cancer lines for cellular proliferation,
we studied these lines for growth following induction of shRNAs
that target NRAS or KRAS. We found that, consistent with the
loss of downstream signaling following abrogation of KRAS in
HCT116 and NRAS in IPC298, cell proliferation was reduced by
40% and 60% respectively (Figure 1B). We found a similar trend
in proliferation with a second shRNA that targeted KRAS or
NRAS in these lines (data not shown). Compared to the RAS
knock-down lines, the luciferase control lines showed no effect on
proliferation following dox induction (Figure 1B). In addition to
the effect seen on proliferation, RAS knock down led to a 5-6-fold
decrease in anchorage-independent growth in both the HCT116
and IPC298 cells (Figure 1C and 1D). These results demonstrate
that both lines were dependent on RAS, KRAS in HCT116 and
NRAS in IPC298, for their proliferation and anchorage-
independent growth. We next tested the relevance of oncogenic
RAS in the RAS-mutant lines for tumor formation in vivo by
establishing s.c. tumors and inducing the targeting shRNA in
established tumors as described in materials and methods. As
shown in Figure 1E and G, the control luciferase oligo induction
had no effect on the growth of HCT116 or IPC298 in vivo.
However, knocking down KRAS in HCT116 (Figure 1F) and
NRAS in IPC298 (Figure 1H) led to a significant delay in tumor
growth, indicating the requirement of KRAS in HCT116 and
NRAS in IPC298 for tumor growth in vivo.
Differential effects of targeting downstream RAS-
effectors on tumor growth in RAS mutant cancer cells
RAS predominantly engages the RAF pathway and the PI3K
pathway as major downstream effectors in various cancers. We
sought to examine the contribution of these two arms in tumor
growth and progression. In addition to elucidating the role of these
two RAS-effector arms in cancer, this knowledge should provide
insight into targeting RAS-driven tumors. We therefore generated
pools of either HCT116 or IPC298 cells harboring inducible
shRNAs that target, BRAF, CRAF, MEK1, MEK2 and PIK3CA
either singly or in various combinations within the same line. We
then tested these lines for in vitro proliferation and in vivo tumor
growth.
HCT116-BRAF knockdown line, upon dox treatment showed
reduction in BRAF protein levels and a concomitant decrease in
phospho ERK levels relative to the total ERK levels (Figure 2A).
Similarly, HCT116-PIK3CA knockdown lines when treated with
dox showed a reduction in the levels of PIK3CA and a decrease in
phospho AKT compared to the control un-induced cells. In
proliferation studies, both the dox treated PIK3CA knockdown
and BRAF knockdown HCT116 lines showed a 20–25%
reduction in proliferation compared to non-dox treated cells
(Figure 2B). However, in vivo, mice bearing tumors derived from
PIK3CA knock-down HCT116-cells, showed no effect on tumor
growth following dox treatment (Figure 2C). These results are
consistent with the fact that the mutant PIK3CA in HCT116 did
not functionally substitute for KRAS in experiments where KRAS
was silenced, both in vitro and in vivo (Figure 1B and 1F). In contrast
to knock-down of PIK3CA in HCT116, nude mice bearing
subcutaneous tumors resulting from injected HCT116 BRAF-
inducible shRNAs cells, when treated with dox showed a delay in
tumor growth (Figure 2D). The delay was not statistically
significant, in part due to the outlier tumor volumes observed
towards the end of this study. However, this could also be in part
due to the fact that the oncogenic RAS could engage other RAF
family members like CRAF and continue to promote tumor
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RAF arm that could result from engagement of other RAFs, we
generated HCT116 inducible shRNA knock-down lines where we
conditionally silenced CRAF or both CRAF and BRAF together.
As expected, knock-down of BRAF and CRAF together decreased
pMEK level completely, while knock-down of CRAF alone
showed some residual pMEK levels (Figure 3A). Consistent with
this finding, the BRAF/CRAF double knock-down line showed a
decrease in pERK levels while the CRAF knock-down alone did
not substantially affect pERK levels in vitro. However, knock-down
of either CRAF or BRAF and CRAF together decreased pAKT
levels (Figure 3A). In proliferation studies, CRAF knock-down
lines showed a ,25% decrease in proliferation, while the
combined CRAF and BRAF knock down had ,40% reduction
in proliferation (Figure 3C). In vivo, combined CRAF and BRAF
knock-down showed a significant delay in tumor growth compared
to the un-induced control (Figure 3E). Although not as significant
as the dual RAF knock-down, CRAF knock-down alone
significantly delayed tumor growth (Figure 3D). These results
suggest that KRAS in HCT116 cells engages both CRAF and
BRAF for promoting tumor growth with CRAF being the
dominant effector arm.
Given that several Mek inhibitors are in development in the
clinic we sought to test if targeting the RAF effectors MEK1 or
MEK2 either alone or together in the same pool of cells would be
as effective as targeting the RAFs. We therefore generated
HCT116 cells that inducibly express shRNAs targeting MEK1
or MEK2 or both. In these lines upon dox addition, MEK1 in the
MEK1-knock-down line, MEK2 in the MEK2-knock-down line,
and both MEK1 and MEK2 in the double knock-down line were
decreased, compared to the un-induced control (Figure 3B). While
the MEK1 or MEK2 knock-down alone did not show a substantial
decrease in phospho ERK levels, the double knock-down showed a
significant decrease in phopsho ERK levels (Figure 3B). However,
knock-down of MEK either alone or in combination does not
affect pAKT level (Figure 3B). We tested these lines in vitro for their
ability to proliferate in the presence or absence of dox and found
that the MEK1, MEK2 and MEK1+2 double lines showed
,15%, ,20% and ,30% reduction in proliferation respectively,
compared to untreated control cells (Figure 3C). This suggests that
loss of each isoform of MEK has an effect on its own, while the
combined knock-down has the most effect on proliferation. We
tested the MEK-knock-down HCT116 lines in vivo for tumor
growth in nude mice and found that silencing both MEK1 and
MEK2 together led to a significant delay in tumor growth
(Figure 3G), compared to targeting them individually (Figure 3F).
To confirm this further we tested a pharmacological inhibitor of
MEK on HCT116 cells and found that it is effective in delaying
Figure 1. KRAS or NRAS, in RAS mutant lines, is required for cell proliferation, anchorage independent growth and in vivo tumor
growth and progression. (A) Western blot analysis of KRAS and NRAS knock-down in HCT116 and IPC298 cells, respectively. Lysates from cells
expressing KRAS, NRAS or control luciferase (shLUC) shRNA, prepared 72 h post treatment with dox, were analyzed, as indicated, by immunoblotting.
b-actin levels in the blot serves as a loading control. (B) Proliferation of KRAS or NRAS shRNA expressing cells after 4 days post dox treatment. (C–D)
KRAS and NRAS shRNA induction, in HCT116 and ICP298 respectively leads to reduced anchorage independent growth of these cells. Representative
images (C) and colony count (D) are shown. (E–H) RAS knock-down, KRAS in HCT116 (F), and, NRAS in IPC298 (H), delays in vivo tumor growth.
Induction of LUC shRNA in control cells (E, G) had no effect on tumor growth. Each data point is the mean6SEM tumor volume derived from 10 mice.
Dotted line in (E–H) represents data from dox treated animals.
doi:10.1371/journal.pone.0005717.g001
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mutant HCT116 colon cancer cells, the RAF/MEK/ERK
effector arm is necessary for cellular proliferation and tumor
growth, despite the presence of activating mutation in PIK3CA.
We extended these studies to the NRAS mutant melanoma
IPC298 cells. Given that BRAF is more commonly mutated in
melanomas, we hypothesized that targeting the BRAF effector
arm alone would be sufficient to affect cell proliferation and in vivo
tumor growth. To test this, we generated a stable pool of IPC298
cells harboring an inducible BRAF shRNA. Upon BRAF shRNA
induction, we observed a significant decrease in the BRAF protein
(Figure 4A). In vitro the BRAF-shRNA expressing IPC298 cells
showed a ,20% decrease in proliferation upon dox treatment
relative to the uninduced control cells (Figure 4C). However, in
vivo, we found that BRAF silencing did not show a statistically
significant delay in IPC298 tumor growth (Figure 4D). This is
contrary to our initial hypothesis about BRAF playing a dominant
role in tumor cell signaling in melanomas bearing an NRAS
mutation. The lack of efficacy in IPC298 cells following BRAF
knock-down could be the result of mutant RAS engaging other
RAF family member like CRAF. To address this, we generated
and tested IPC298 pools that inducibly expressed shRNAs
targeting CRAF alone or BRAF and CRAF in combination.
Upon induction of corresponding shRNA in these cells, CRAF or
BRAF and CRAF proteins were completely depleted leading to a
decrease in pMEK and pERK levels (Figure 4A). As with BRAF,
knock-down of CRAF also decreased in vitro cell proliferation by
,20%. We found double knock-down of both BRAF and CRAF
to be far more effective leading to a ,50% reduction in cell
proliferation compared to the uninduced cells (Figure 4C). Similar
to the effects observed with BRAF knock-down, silencing CRAF
alone did not show a statistically significant delay in IPC298 tumor
growth in vivo (Figure 4E). In contrast, mice bearing IPC298 co-
expressing BRAF and CRAF shRNA showed complete inhibition
of tumor growth following dox induction (Figure 4F). These data
indicate that the NRAS mutant IPC298 melanoma line engages
both the BRAF and CRAF effector arms for survival and
proliferation and that targeting both BRAF and CRAF is
important for efficacy. Further, both pERK and pAKT levels
are decreased only when both BRAF and CRAF are knocked
down together (Figure 4A), suggesting that signaling from both the
RAF and PI3K effectors need to be inhibited for efficacy.
Figure 2. Effect of BRAF and PIK3CA knock-down on KRAS
G13D mutant HCT116 cell growth. (A) Western blot analysis of PIK3CA or BRAF
knock-down in HCT116 at 72 h post dox induction of relevant shRNAs. The effect of knock-down on the phosphorylation status of relevant
downstream targets is shown. (B) Proliferation of BRAF and PIK3CA shRNA expressing cells 4 days post dox treatment. (C) shRNA targeting PIK3CA
when induced in mice bearing HCT116 tumors did not delay tumor growth. (D) BRAF knock-down in HCT116 derived tumors shows a trend towards
delayed tumor growth. Each data point is the mean6SEM tumor volume derived from 10 mice. Dotted line in (C, D) represents data from dox treated
animals.
doi:10.1371/journal.pone.0005717.g002
RAS Targeting in Cancer
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MEK1 and MEK2, we sought to understand the effect of targeting
MEKs in IPC298 cells. We generated and tested IPC298 pools
that inducibly expressed shRNAs that target RAF-effectors MEK1
or MEK2 or both MEK1 and MEK2 together in the same cells.
The targeted knock-down of MEK1 or MEK2 alone or a
combined MEK1 and MEK2 knock-down reduced the levels of
these proteins (Figure 4B). The pERK levels were also decreased
in these cells compared to control untreated cells (Figure 4B). In all
the MEK-shRNA containing IPC298 lines, in vitro we did not
observe a significant difference in proliferation between the control
and dox-treated cells (Figure 4B). Similarly, silencing MEK1 or
MEK 2 alone or in combination, did not show a significant delay
in tumor growth relative to the control animals (Figure 4G). This
result was unexpected given that CRAF and BRAF targeting was
effective, suggesting potential differential survival and proliferation
signaling outputs resulting from inhibition of different nodes along
the RAS/RAF pathway. Consistent with this, we find pAKT levels
to be unchanged (Figure 4B) in the MEK1/2 double knock-down
line, although pERK was decreased. This is in contrast to
decreases in both the pAKT and pERK levels observed with the
BRAF/CRAF double knock-down lines (Figure 4A). Further, this
is a likely reason for the lack of efficacy observed in the combined
MEK1/2 knock-down as compared to BRAF/CRAF double
knock-down. Although the exact cross talk and feedback
mechanism leading to the differential modulation of pAKT and
pERK in response to knock-down of the various RAF and RAF-
effectors is not obvious, this data indicates the requirement for
targeting signaling from both ERK and AKT effectors in NRAS
mutant lines.
Combined targeting of RAF and PI3K, RAS-effector arms
effectively reduces tumor growth in NRAS mutant
tumors
Given the observed requirement for decrease in both pERK
and pAKT downstream of mutant NRAS and the intense efforts
to develop inhibitors targeting BRAF, MEK1/2 and PI3K in
progress, we sought to understand if combined knock-down of
RAF or MEK with PI3K would be an effective strategy for
treatment of NRAS mutant melanomas.
Induction of shRNA targeting PIK3CA alone reduced the levels
of PIK3CA, leading to a reduction in the pAKT levels (Figure 5A).
Figure 3. RAF or MEK1-MEK2 double knock-down delays growth of KRAS
G13D mutant HCT116 cells in vivo. (A–B) Western blot analysis
of CRAF or CRAF and BRAF or MEK1 and MEK2 knock-down in HCT116 at 72 h post dox induction of relevant shRNAs. The effect of knock-down on
the phosphorylation status of relevant downstream target is shown. (C) Proliferation of CRAF, CRAF and BRAF, MEK1, MEK2 and double MEK1+2
shRNA expressing cells 4 days post dox treatment. (D–G) shRNA targeting CRAF (D), CRAF and BRAF (E) and MEK1 and MEK2 double knock-down (G)
in KRAS-mutant HCT116 tumors in vivo delayed tumor growth. shRNA targeting MEK1 or MEK2 individually (F) when induced in mice bearing HCT116
tumors did not delay tumor growth. Each data point is the mean6SEM tumor volume of 10 mice. Dotted line in (D–F) represents data from dox
treated animals.
doi:10.1371/journal.pone.0005717.g003
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PIK3CA shRNA line did not show any significant decrease in
proliferation following dox treatment, compared to untreated cells
(Figure 5B). In vivo, induction of PIK3CA targeting shRNA, did
not delay IPC298 tumor growth, compared to animals that were
placed on sucrose (Figure 5C). This suggested that targeting the
PIK3CA effector arm alone was not sufficient to prevent tumor
growth in the NRAS mutant line.
To test the possibility that the combined targeting of RAF and
PI3K effector arms would be effective in the NRAS mutant
background, we generated IPC298 pools that inducibly expressed
shRNAs that target either PIK3CA and BRAF together or
PIK3CA along with both the RAF-effectors, MEK1 and 2. These
cells were characterized for effective knock-down of BRAF, MEKs
and PIK3CA. As expected, upon dox treatment the cells showed
reduced BRAF, PIK3CA or MEK1 and 2 protein (Figure 5A).
Consistent with this, pERK and pAKT levels were diminished,
relative to the total amount of ERK and AKT respectively. It is
interesting to note that while BRAF or PIK3CA knock-down
alone did not affect pERK levels significantly, the combined
knock-down of BRAF and PIK3CA led to significant decrease in
pERK and pAKT. We studied these cells in proliferation assays
and found that there was a ,25–30% decrease in proliferation
when both BRAF and PIK3CA or the RAF-effectors MEK1, 2
and PIK3CA together were knocked down in the IPC298 cells
(Figure 5B). We also tested these lines in vivo to see if targeting both
BRAF and PIK3CA or both MEK1+2 and PIK3CA will lead to
delayed tumor growth. Targeting both the RAS-effector arms,
either by combined BRAF and PIK3CA or MEK1+2 and
PIK3CA together, effectively delayed the tumor growth
(Figure 5D and 5E) confirming the importance of both the PI3K
and RAF effector arms in the IPC298 NRAS-mutant melanoma
line for tumor growth.
In order to understand if other NRAS mutant lines employ
similar signaling cascades downstream of NRAS, we chose to
study SK-MEL-30, another melanoma line with an NRAS
Q61K
mutant allele. We generated SK-MEL-30 cells bearing inducible
shRNA that target NRAS, BRAF, CRAF, PIK3CA alone, or
combinations of BRAF and CRAF, or BRAF and PIK3CA.
Inducible knock-down of NRAS, BRAF, CRAF individually or
BRAF and CRAF or BRAF and PIK3CA together showed a
decrease in the appropriate target protein with concomitant
Figure 4. BRAF/CRAF double-knock-down delays growth of NRAS
Q61L-mutant IPC298 melanoma cells in vivo. (A–B) Western blot
analysis showing BRAF, CRAF, BRAF+CRAF, MEK1, MEK2, and double MEK1/2 knock-down in IPC298 at 72 h after dox induction of shRNAs. The effect
of knock-down on the phosphorylation status of relevant downstream targets is shown. (C) Effect of expressing BRAF, CRAF, BRAF+CRAF, MEK1,
MEK2 and double MEK1+2 shRNAs on proliferation of IPC298 cells 4 days following dox treatment. (D–G) While shRNA targeting BRAF+CRAF (F)
together delayed tumor growth, shRNA targeting BRAF (D), CRAF (E), MEK1, or MEK2 or MEK1 and MEK2 together (G) when induced in mice bearing
IPC298 derived tumors did not delay tumor growth. Each data point is the mean6SEM tumor volume of 10 mice. Dotted line in (D–G) represents data
from dox treated animals.
doi:10.1371/journal.pone.0005717.g004
RAS Targeting in Cancer
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5717changes in downstream signaling as indicated by decreases in
pERK and/or pAKT levels (Figure 6A, 6B, 7A). As with IPC298,
knock-down of NRAS or the combined knock-down of BRAF and
CRAF or BRAF and PI3KCA was effective in decreasing both the
pERK and pAKT (Figure 6A, 6B, 7A). In in vitro proliferation
studies, induction of shRNA targeting NRAS, BRAF, CRAF, dual
targeting of BRAF/CRAF, or BRAF/PIK3CA had a reduction in
proliferation of ,20%, ,12%, ,20%, ,40% and ,28%,
respectively (Figure. 6C and 7B), while the control shLUC or
shRNAs targeting PIK3CA did not have a significant effect on
proliferation compared to un-induced cells (Figure. 6C and 7B). In
in vivo tumor growth studies, tumors carrying shRNAs that target
NRAS alone, or combinations of BRAF and CRAF, or BRAF and
PIK3CA, showed a significant delay in tumor growth (Figure 6E,
6H and 7D) compared to the corresponding sucrose controls. As
observed in IPC298 cells, targeting BRAF, CRAF or PIK3CA
individually in SK-MEL-30 cells did not effect in vivo tumor
growth (Figure 6F, 6G and 7C). These results further confirm the
requirement for sustained decrease in pERK and pAKT mediated
signaling achieved either through combined targeting of BRAF
and CRAF or BRAF and PIK3CA effector arms to be a more
general requirement for effective therapy in NRAS mutant
tumors.
RAS-effector targeting promotes cell cycle arrest
To address the mechanism by which loss of RAS (KRAS in
HCT116 and NRAS in IPC298) reduced cellular proliferation and
delayed tumor growth, we analyzed cell cycle progression and
apoptosis induction in these cells following dox treatment.
Induction of NRAS shRNA expression in the NRAS mutant-
IPC298 line led to ,65% of the cells arresting in G1 compared to
,47% of the cells in G1 in untreated cells. This led to a delayed
entry into S and G2/M phase (Table 1 and Figure 8). In the
KRAS mutant HCT116 cells, KRAS knock-down following
KRAS shRNA induction, lead to the cells accumulating in S
phase, thereby preventing G2/M progression (Table 1 and
Figure 8).
Given that BRAF, CRAF, BRAF+CRAF and MEK1+2 double
knock-down had an adverse effect on HCT116 cell proliferation
and tumor growth, we examined the effect of targeting these genes
on cell cycle progression. In all these knock-down cells, targeting
the expression of these proteins led to an accumulation in G1 or S-
Figure 5. Combined targeting of PIK3CA+BRAF, and PIK3CA+MEK1/2 in NRAS
Q61L-mutant IPC298 melanoma cell delays tumor
growth in vivo. (A) Immuno blot analysis of PIK3CA, PIK3CA+BRAF, and PIK3CA+MEK1/2 knock-down in IPC298 cells affects phosphorylation of
downstream targets. (B) Proliferation of IPC298 cells expressing shRNAs targeting PIK3CA alone or PIK3CA and BRAF together or PIK3CA together
with MEK1/2 4 days after dox treatment. (C) shRNA targeting PIK3CA in IPC298 did not delay tumor growth in vivo, following induction of PIK3CA
targeting shRNA. (D–E) Combined induction of BRAF and PIK3CA shRNA together or MEK1 and 2 together with PIK3CA in mice bearing IPC298
derived tumors delay tumor growth in vivo. Each data point is the mean6SEM tumor volume of 10 mice. Dotted line in (C–E) represents data from
dox treated animals.
doi:10.1371/journal.pone.0005717.g005
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Figure 8). These results suggest that targeting RAS and its
downstream effector RAFs and the RAF-effectors MEK1+2 are
mechanistically equivalent in KRAS mutant HCT116 cells. This is
consistent with the fact that targeting RAS, BRAF, CRAF,
BRAF+CRAF or MEK1+2 in HCT116 resulted in decreased
proliferation in vitro and delayed tumor growth in vivo. Consistent
with in vitro proliferation and in vivo tumor growth data, knock-
down of BRAF, MEK1/2, and PIK3CA in IPC298 cells did not
delay cell cycle progression (Table 1 and Figure 8). In contrast,
knock-down of BRAF+CRAF, BRAF+PIK3CA, and MEK1/
2+PIK3CA in IPC298 cells led to accumulation of cells in S or
G1-phase consistent with the adverse effect on tumor growth
observed in vivo.
To further dissect the mechanisms by which RAS targeting
affects cell proliferation and delays tumor growth we tested the
cells following RAS-targeting for apoptosis by annexin-V staining.
As shown in Supplementary Figure 2, at the time-point observed,
no increase in annexin-V staining was detected following RAS-
knock-down in RAS-mutated IPC298 and HCT116 cells.
However, BRAF knock-down in HCT116 showed a slight increase
in annexin-V staining compared to the un-induced line, whereas
all the other knock-down lines did not show an in increase in
annexin-V staining following dox treatment. These data indicate
that inhibition of cell proliferation and tumor growth upon RAS or
a downstream RAS-effector knock-down is mainly due to delayed
cell cycle progression.
Discussion
Understanding the relative importance of oncogenic RAS
effectors in tumor formation is fundamental to targeting RAS
driven tumors using combinations of pharmacological inhibitors
that are either available or in development. In this study we have
addressed the relative importance of the RAS-effectors, RAF and
PI3K, in a RAS mutant context in human tumor lines both in vivo
and in vitro using a regulatable RNA interference system. We show
that HCT116 colon tumor cells bearing an oncogenic KRAS
G13D
mutation, IPC298 melanoma cells carrying an activated allele of
NRAS
Q61L and SK-MEL-30 carrying a mutant NRAS
Q61K allele
are dependent on the RAS pathway for their growth and
proliferation both in vitro and in vivo. Knock-down of these RAS
alleles in vivo leads to a significant delay in tumor growth and is
consistent with the cell cycle arrest observed in the knock-down
line in vitro. This is in agreement with a previous study in nude
mice that demonstrated the requirement of mutant RAS for tumor
formation, [16,31]. To address the relevance of the effector arms
of RAS in tumor maintenance and growth, we targeted the major
Figure 6. Combined targeting of BRAF and CRAF in NRAS
Q61K-mutant SK-MEL-30 melanoma cell delays tumor formation in vivo. (A–
B) Immunoblot analysis of SK-MEL-30 cells expressing control luciferase shRNA or shRNAs targeting NRAS, BRAF, CRAF or both BRAF and CRAF reveals
respective protein knock-down and their effects on phosphorylation of downstream targets. (C) Proliferation of SK-MEL-30 cells expressing control
luciferase shRNA or shRNAs targeting NRAS, BRAF, CRAF or both BRAF and CRAF. (D–H) shRNA targeting NRAS (E) or both BRAF and CRAF in SK-MEL-
30 (H) delays tumor growth in vivo, whereas, induction of BRAF (F), CRAF (G) targeting shRNA or control luciferase (D) shRNA did not affect tumor
growth. Each data point is the mean6SEM tumor volume of 10 mice. Dotted line in (D–H) represents data from dox treated animals.
doi:10.1371/journal.pone.0005717.g006
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In HCT116, a colon cancer line, that carries a mutant KRAS
allele, we find that interfering with the RAF effector axis at the
level of RAF (BRAF and CRAF) and MEK (MEK1 and MEK2)
was effective in delaying tumor growth. In contrast, there was no
effect on tumor growth and maintenance when PIK3CA alone
was knocked down, despite the fact that PIK3CA is mutated in this
line. It is possible that in HCT116 cells, RAS could engage other
PI3K family members to promote tumor growth. This is unlikely
as pAKT levels are reduced following PIK3CA knock-down
indicating that PIK3CA is the major PI3K isoform engaged by
RAS in these cells. Further, this data suggest that the RAF-MEK-
ERK cascade is predominantly engaged by KRAS in these cancer
cells for growth and proliferation. In HCT116 cells, knock-in
mutations that revert the mutant PIK3CA to WT affects it ability
to proliferate, migrate and metastasize [9]. However, consistent
with our in vivo data an HCT116 PIK3CA wild type line generated
by knocking-in a copy of the WT PIK3CA in place of the mutant
Figure 7. Combined targeting of PIK3CA and BRAF together in NRAS
Q61K-mutant SK-MEL-30 melanoma cell delays tumor
formation in vivo. (A) Immunoblot analysis of SK-MEL-30 cells expressing shRNAs targeting PIK3CA or both PIK3CA and BRAF reveal respective
protein knock-down and their effects on phosphorylation of downstream targets. (B) Proliferation of SK-MEL-30 cells expressing control luciferase
shRNA or shRNAs targeting PIK3CA or both PIK3CA and BRAF. (C–D) shRNA targeting both PIK3CA and BRAF in SK-MEL-30 (D) delays tumor growth in
vivo, whereas, induction of PIK3CA (C) targeting shRNA alone did not affect tumor growth. Each data point is the mean6SEM tumor volume of 10
mice. Dotted line in (C–D) represents data from dox treated animals.
doi:10.1371/journal.pone.0005717.g007
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sub-cutaneous tumors [9]. Also, recently a study of colon cancer
patients showed that PIK3CA mutations did not confer any
significant effect on mortality among patients with KRAS-mutated
tumors and is consistent with our findings on tumors growth in
HCT116 cells [32]. These data taken together with our findings
suggest that, in the colon cancer line, KRAS predominantly
engages the RAF-MEK-ERK effector arm. This is in contrast to
studies in other tumor types where the PIK3CA pathway is shown
to be sufficient for tumor initiation and maintenance.
Our data shows that effective targeting of mutant NRAS driven
tumor requires sustained reduction in pAKT and pERK. This can
Figure 8. Targeting RAS and its downstream effectors leads to delay in cell cycle progression. A representative image showing the effect
on cell cycle progression following knock-down of RAS and its downstream effectors as indicated in HCT116 or IPC298 cells. The complete results of
cell cycle analysis from triplicates of two independent experiments along with the standard error of the mean values are presented in Table 1.
doi:10.1371/journal.pone.0005717.g008
Table 1. Cell cycle status after RAS, RAF, PI3KCA and MEK knockdown.
Cell lines G1 phase S phase G2 phase
No Dox Dox No Dox Dox No Dox Dox
HCT116-RAS 63.5960.9 55.3060.9
** 17.6560.7 30.7660.3
*** 18.7760.3 13.9460.6
IPC298-NRAS 47.1860.9 65.1461.9
*** 34.1561.8 22.3361.8
* 18.6761.8 12.5360.1
*
HCT116-BRAF 67.0861.1 66.5461.8 15.8861.2 23.1260.9
** 17.0560.1 10.3460.9
**
IPC298-BRAF 56.1761.0 51.5963.6 24.4263.3 30.4762.3 19.4162.4 17.9461.4
HCT116-CRAF 69.3761.1 66.1162.0 22.5060.3 26.0561.2
* 8.1360.8 7.8460.9
IPC298-CRAF 50.2961.1 55.0561.4 34.9860.6 31.1760.2
* 15.4061.8 13.7861.4
HCT116-BRAF+CRAF 70.9260.5 74.5960.9
* 20.8960.2 18.2960.7
* 8.1860.4 7.1260.2
IPC298-BRAF+CRAF 49.8860.7 70.8960.4
*** 38.8560.3 21.4160.4
*** 13.2860.3 7.7060.3
***
HCT116-PI3KCA 74.0660.8 71.6561.2 16.0260.4 15.7360.3 9.9160.4 12.6160.4
IPC298-PI3KCA 49.8961.6 51.9960.7 39.9360.8 38.6460.3 10.1861.0 9.3760.5
HCT116-MEK1+2 63.5960.9 55.3060.9
** 17.6560.7 30.7660.3
*** 18.7760.3 13.9460.6
**
IPC298-MEK1+2 55.3560.2 54.0960.6 34.8760.7 34.1960.5 9.7960.5 11.7260.3
IPC298-BRAF+PI3KCA 51.1860.4 55.5461.3
* 37.1460.4 34.1960.6
* 11.6760.4 10.2760.7
IPC298-PI3KCA+MEK1+2 51.4560.8 56.9360.9
** 32.7061.3 29.8560.9 14.5261.8 13.9260.3
*p,0.05, **p,0.01 and ***p,0.001 with respect to no dox control of same cell cycle phase.
doi:10.1371/journal.pone.0005717.t001
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PIK3CA and BRAF or PIK3CA and MEK1+2. However,
inhibition of MEK1+2 alone in the NRAS mutant line was not
equivalent to inhibiting BRAF and CRAF together, as assessed by
pERK and pAKT, suggesting the presence of differential signaling
and feedback effects that arise from perturbing different nodes
along the RAS/RAF signaling cascade. This is consistent with
previously reported feedback and cross talk between the RAF and
PI3K pathways [33]. These results have implications for
therapeutic targeting of NRAS mutant melanomas where a dual
BRAF/CRAF inhibitor or a BRAF and a PIK3CA inhibitor or a
MEK and a PIK3CA inhibitor in combination is likely to show
efficacy in the clinic. It is interesting to note that several studies
also suggest the relevance of combined inhibition of CRAF and
BRAF in a BRAF mutant context for efficacy and may prove to be
relevant strategy for treatment of both NRAS and BRAF mutant
melanomas [34,35].
Our data suggests that the pathways engaged by mutant RAS
that promote tumor formation show differences that are possibly
inherent to each tissue or tumor type. Further investigation of the
RAS-effector arms engaged within each tumor type may reveal
differences that correlate with known tumor subtypes or form the
basis for a better molecular classification of tumor subtypes. In the
clinical context, understanding the specific effector arms engaged
by RAS in driving tumorigenesis is critical to successfully treating
these cancers. Developing gene signatures that allow identification
and classification of tumors into RAS effector classes, based on
effectors engaged by RAS, should allow for rational patient
therapies that utilize appropriate pharmacological inhibitors either
alone or in combination.
Materials and Methods
Cell lines and antibodies
Colon cancer cell line HCT116 was purchased from ATCC
(American Type Culture Collection, Manassas, VA). IPC-298, a
cutaneous melanoma line and SK-MEL-30, a melanoma line,
were obtained from German Collection of Microorganisms and
Cell Cultures (DMZ, Braunschweig, Germany). Mutation status of
the cell lines used in this study is listed in Table-S1. Antibodies
used in the study are as follows: CRAF, pAKT, AKT, ERK2, p-
ERK1/2 (Thr202/Tyr204), MEK1, MEK2 and p-MEK1/MEK2
(Ser217/221) (Cell Signaling Technology, Beverly, MA); BRAF
and NRAS (F-7; Santa Cruz Biotechnology, Santa Cruz, CA);
KRAS (Novus Biologicals, Littleton, CO), PIK3CA (Millipore,
Temecula, CA), b-actin (Sigma Life Science, St. Louis, MO); and
horseradish peroxidase (HRP)–conjugated secondary antibodies
(Pierce Biotechnology, Rockford, IL).
Generation of inducible-shRNA cell pools
Hairpin oligonucleotides used in this study are listed in the
Table-S2. They were based on a collection of siRNAs from
Dharmacon Inc., (Chicago, IL) or based on previously published
shRNAs [29,30]. Inducible-shRNA bearing lentivirus constructs
were made based on previously described methods [29,30] by co-
transfecting pHUSH-Lenti-GFP or pHUSH-Lenti-dsRed con-
structs containing a desired shRNA with plasmids expressing the
vesicular stomatitis virus (VSV-G) envelope glycoprotein and
HIV-1 packaging proteins (GAG-POL) in HEK293T cells using
Lipofectamine (Invitrogen, Carlsbad, CA). Target cells were
transduced with these viruses and sterile sorted (top 10%) by flow
cytometry for presence of dsRed or GFP or both. Cells were
characterized for knock-down by western blot analysis as
previously described [29,30].
Anchorage independent growth assay
Twenty thousand cells in media containing 0.35% agarose with
or without 1.0 mg/ml dox was plated on a layer of 0.5% agar in
10% serum. After a 2-week incubation at 37uC colonies were
stained with 1 mM Calcein-AM, imaged using ImageXpress Micro
(Molecular Devices, Sunnyvale, CA) and processed using MetaX-
press Version 2.0 (Molecular Devices, Sunnyvale, CA) software to
obtain colony counts.
Xenograft studies
Six- to eight-week-old female athymic nu/nu mice were obtained
from Charles River Laboratories (Wilmington, MA). For xenograft
studies following trypsinization 5610
6 HCT116 cells or 1610
7
IPC298 or SK-MEL-30 were resuspended in 200 ml of PBS and
injected into the right flank of nude mice. Once the tumors
reached a mean volume of 150 to 200 mm
3, the mice with
similarly sized tumors were grouped and put on either 5% sucrose
solution containing 1 mg/mL dox, for the treatment arm, or 5%
sucrose only for the animals in control arm. Dox treatment induces
the relevant shRNA. Tumor growth was monitored twice weekly
for 4–8 weeks using calipers. Also, the mice were weighed twice a
week. Mice whose tumor burden reached 2,000 mm
3 were
euthanized. Between 8 and 10 mice were used for each treatment
group and results are presented as mean tumor volume6SEM.
Cell Proliferation
In order to assess proliferation, 1610
4 cells/well in 100 ml
volume was plated in a 96-well plate. Cells were treated with
1 mg/ml dox and proliferation was assessed after 4 days using Cell
Titer-Glo Luminescent Cell Viability Assay kit (Promega Corpo-
ration, Madison, WI). A standard curve of luminescence as a
function of cell number was used to calculate the number of cells
in each treatment. Data are presented as mean6SEM from at
least three replicate experiments.
Cell cycle analysis
Cells were seeded in 6 well plates and treated with 1 mg/ml dox.
After 72 h, cells were fixed in 70% ethanol for 1 hr at 4uC and
stained with propidium iodide (PI) staining solution (50 mg/ml PI
and 500 mg/ml DNase free RNase in PBS) and analyzed by flow
cytometry (BD FACScan) using the CellQuest program. The data
were analyzed using Mod Fit LT 3.0 cell cycle analysis software.
Apoptosis assay
We used annexin V to measure the levels of apoptosis. Briefly,
4610
5 cells, RAS, BRAF and MEK1+2 shRNA containing
HCT116 or IPC298 stable cells, were plated in 6-well plates and
treated with dox (1 mg/ml for 72 hrs) in triplicate before staining
with annexin V. After treatment cells were harvested, washed once
with PBS, stained with FITC-conjugated anti-annexin V antibody
and 100 mg/ml of propidium iodide in binding buffer for 15 min
at room temperature. The cells were then analyzed with a flow
cytometer (BD FACSCalibur). Background green fluorescence
intensity due to presence of MEK1-shRNA-GFP in MEK1+2 cells
were subtracted out before the calculating the fraction of annexin-
V positive cells in case of MEK1+2 cells.
Statistical Analysis
Student’s t-test (two-tailed) was used for statistical analyses to
compare treatment groups using GraphPad Prism 5.00 (GraphPad
Software, San Diego, CA). A P-value ,0.05 was considered
statistically significant (*p,0.05, **p,0.01 and ***p,0.001).
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Figure S1 MEK inhibitor is effective in KRAS mutant HCT116
cells. Treatment of HCT116 tumor-bearing mice with small
molecule MEK inhibitor resulted in significant inhibition of tumor
growth (p,0.001). Doses were well tolerated as determined by the
change in animal weight (data not shown). MEK small molecule
inhibitor was administered daily by oral gavage at a final
concentration of 6 mg/kg. The compound was prepared fresh
weekly in 0.5% methylcellulose and 0.2% Tween 80 in water and
stored at 4uC. Tumor growth was monitored twice weekly for 4–8
weeks using calipers.
Found at: doi:10.1371/journal.pone.0005717.s001 (0.02 MB TIF)
Figure S2 Induction of apoptosis measured by Annexin-V
staining, in RAS mutant lines following induction of shRNA.
Apoptosis in HCT116 or IPC298 lines expressing shRNAs that
target KRAS or NRAS (A), BRAF (B) and both MEK1 and MEK2
(C). Results shown are mean6SEM of experiments from triplicates
of two independent experiments. *P,0.001 vs untreated cells.
Found at: doi:10.1371/journal.pone.0005717.s002 (0.14 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0005717.s003 (0.04 MB TIF)
Table S2
Found at: doi:10.1371/journal.pone.0005717.s004 (0.21 MB TIF)
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